{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-013852","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.528321+00:00","generated_at":"2026-06-25T13:28:28.851203+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M","bullets":["Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.","Gross margin 48% vs 46% prior year; DSO decreased 27% to 63 days.","Adjusted EBITDA loss $0.9M, flat YoY; cash $2.9M at March 31, 2022.","Entered $2M convertible note agreement with BroadOak Fund V, L.P. on May 5, 2022 for working capital.","Collaboration with Twist Bioscience and Miroculus to automate NGS library prep using digital microfluidics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-013852","json":"https://secwatch.observer/filing/0001493152-22-013852.json","markdown":"https://secwatch.observer/filing/0001493152-22-013852.md","text":"https://secwatch.observer/filing/0001493152-22-013852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/0001493152-22-013852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222013852/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T13:28:28.851203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}